Do meropenem and polymyxin provide gram-positive coverage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Gram-Positive Coverage of Meropenem and Polymyxin

Meropenem provides moderate gram-positive coverage against methicillin-susceptible staphylococci and most streptococci, but polymyxin has NO gram-positive activity whatsoever.

Meropenem Gram-Positive Spectrum

Meropenem demonstrates activity against specific gram-positive organisms, though this is not its primary strength 1:

Organisms Covered:

  • Enterococcus faecalis (vancomycin-susceptible isolates only)
  • Staphylococcus aureus (methicillin-susceptible isolates ONLY - MSSA)
  • Streptococcus agalactiae (Group B Strep)
  • Streptococcus pneumoniae (penicillin-susceptible isolates only)
  • Streptococcus pyogenes (Group A Strep)
  • Viridans group streptococci

Critical Limitations:

Meropenem has NO activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE) 1. This is explicitly stated in the FDA label and represents a major gap in coverage.

The drug is 4- to 8-fold less active against oxacillin-susceptible staphylococci compared to imipenem 2, and only has moderate activity against Enterococcus faecalis (mean MIC 5 mg/L) 3.

Polymyxin Gram-Positive Coverage

Polymyxin (both polymyxin B and colistin/polymyxin E) has ZERO gram-positive activity 4. The FDA label explicitly states: "All gram positive bacteria, fungi, and gram-negative cocci are resistant to polymyxin B" 4.

Polymyxin's mechanism of action—disrupting bacterial cell membranes by targeting lipopolysaccharide in the outer membrane—only works against gram-negative bacteria 5. The gram-positive cell wall structure renders these organisms inherently resistant.

Clinical Implications

When using these antibiotics for empiric therapy:

  • If gram-positive coverage is needed (particularly MRSA, enterococci, or resistant streptococci), you MUST add a separate agent such as vancomycin or linezolid 6
  • Meropenem alone may suffice for polymicrobial infections where only methicillin-susceptible staphylococci or susceptible streptococci are concerns
  • Polymyxin contributes nothing to gram-positive coverage and should never be relied upon for these organisms

The WHO guidelines recognize this limitation—when recommending meropenem for severe intra-abdominal infections, they note that ampicillin may need to be added for enterococcal coverage if the regimen doesn't otherwise cover these organisms 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.